Business News • PR NewsWire • New Analyses Presented At ASH 2015 Demonstrate The Potential Of Kyprolis® (Carfilzomib) As Backbone Therapy In Multiple Myeloma

New Analyses Presented At ASH 2015 Demonstrate The Potential Of Kyprolis® (Carfilzomib) As Backbone Therapy In Multiple Myeloma

New Analyses Presented At ASH 2015 Demonstrate The Potential Of Kyprolis® (Carfilzomib) As Backbone Therapy In Multiple Myeloma

THOUSAND OAKS, Calif., Dec. 5, 2015 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the presentation of new key data evaluating Kyprolis® (carfilzomib) -based regimens in patients with relapsed multiple myeloma. The data showed Kyprolis in combination with dexamethasone...

View More : http://www.prnewswire.com/news-releases/new-analyses-presented-at-ash-2015-demonstrate-the-potential-of-kyprolis-carfilz...

Releted News by prnewswire

Approaches to Supportive Care for Blood Disorders Improve Outcomes, Expand Access to Treatment

360 Game Aims to Pave a Path for US Game Developers To Bring Their Games to China

U.S. Census Bureau Daily Feature for December 6: Full Accounting

Riconoscimenti per le migliori aziende italiane nell'ambito di una prestigiosa cerimonia di premiazione

Fat People Have Sex: World's First Body-Inclusive Sex Gear Shop Announces Plans for Physical Store, Launches Crowdfunding Campaign